CUSIP 03969F109 · who reports it, how much, and how much it matters to them
28 of the 720 hedge fund managers we track reported shares of Arcus Biosciences, Inc. (NYSE: RCUS) on Form 13F for 30 June 2026. Between them they reported USD 501m. The largest position belongs to Suvretta Capital Management, at USD 147m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management4 funds on PPLI.com | USD 147m | 2.7% |
| 2 | Citadel Advisors32 funds on PPLI.com | USD 97m | 0.0% |
| 3 | Marshall Wace LLP84 funds on PPLI.com | USD 60m | 0.0% |
| 4 | Samlyn Capital8 funds on PPLI.com | USD 48m | 0.8% |
| 5 | Sofinnova Investments1 fund on PPLI.com | USD 29m | 1.5% |
| 6 | Baker Bros. Advisors2 funds on PPLI.com | USD 26m | 0.1% |
| 7 | Logos Global Management1 fund on PPLI.com | USD 20m | 0.9% |
| 8 | Two Sigma Investments35 funds on PPLI.com | USD 20m | 0.0% |
| 9 | Dafna Capital Management6 funds on PPLI.com | USD 14m | 2.6% |
| 10 | Rock Springs Capital Management2 funds on PPLI.com | USD 5.5m | 0.3% |
| 11 | Boothbay Fund Management2 funds on PPLI.com | USD 4.8m | 0.1% |
| 12 | PFM Health Sciences3 funds on PPLI.com | USD 4.7m | 0.4% |
| 13 | Hudson Bay Capital Management8 funds on PPLI.com | USD 4.3m | 0.0% |
| 14 | Platinum Investment Management11 funds on PPLI.com | USD 4.1m | 1.0% |
| 15 | Millennium Management6 funds on PPLI.com | USD 4.1m | 0.0% |
| 16 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 3.8m | 0.0% |
| 17 | D. E. Shaw & Co.15 funds on PPLI.com | USD 3m | 0.0% |
| 18 | Persistent Asset Partners10 funds on PPLI.com | USD 1.8m | 0.5% |
| 19 | Burkehill Global Management5 funds on PPLI.com | USD 1.5m | 0.1% |
| 20 | Balyasny Asset Management25 funds on PPLI.com | USD 704,000 | 0.0% |
| 21 | Squarepoint Ops7 funds on PPLI.com | USD 467,000 | 0.0% |
| 22 | Entrypoint Capital1 fund on PPLI.com | USD 408,000 | 0.1% |
| 23 | Bayforest Capital1 fund on PPLI.com | USD 392,000 | 0.4% |
| 24 | Capstone Investment Advisors25 funds on PPLI.com | USD 310,000 | 0.0% |
| 25 | Verition Fund Management3 funds on PPLI.com | USD 308,000 | 0.0% |
| 26 | Campbell & Company Investment Adviser8 funds on PPLI.com | USD 290,000 | 0.0% |
| 27 | Seelaus Asset Management8 funds on PPLI.com | USD 202,000 | 0.1% |
| 28 | The Quarry1 fund on PPLI.com | USD 925 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management | USD 147m | 2.7% |
| 2 | Dafna Capital Management | USD 14m | 2.6% |
| 3 | Sofinnova Investments | USD 29m | 1.5% |
| 4 | Platinum Investment Management | USD 4.1m | 1.0% |
| 5 | Logos Global Management | USD 20m | 0.9% |
| 6 | Samlyn Capital | USD 48m | 0.8% |
| 7 | Persistent Asset Partners | USD 1.8m | 0.5% |
| 8 | PFM Health Sciences | USD 4.7m | 0.4% |
| 9 | Bayforest Capital | USD 392,000 | 0.4% |
| 10 | Rock Springs Capital Management | USD 5.5m | 0.3% |
Arcus Biosciences, Inc. trades under the symbol RCUS on the New York Stock Exchange. Its CUSIP, the code used on Form 13F, is 03969F109.
28 of the 720 hedge fund managers PPLI.com tracks reported Arcus Biosciences, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Suvretta Capital Management (USD 147m), Citadel Advisors (USD 97m), Marshall Wace LLP (USD 60m), Samlyn Capital (USD 48m) and Sofinnova Investments (USD 29m).
28 managers in our coverage reported it, and between them they run 344 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Suvretta Capital Management, where the position was 2.7% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Arcus Biosciences, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.